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Abstract
Background: Many guidelines recommend adherence counseling prior to initiating antiretrovirals (ARVs), however the
additional benefit of pre-therapy counseling visits on early adherence is not known. We sought to assess for a benefit of
adherence counseling visits prior to ARV initiation versus adherence counseling during the early treatment period.
Methods: We performed a secondary analysis of data from a prospective cohort of HIV-infected patients in Mbarara,
Uganda. Adults were enrolled upon initiation of ARVs. Our primary exposure of interest was ARV adherence counseling prior
to initiating therapy (versus concurrent with initiation of therapy). Our outcomes of interest were: 1) average adherence
.90% in first three months; 2) absence of treatment interruptions .72 hours in first three months; and 3) Viral load .400
copies/ml at the three month visit. We fit univariable and multivariable regression models, adjusted for predictors of ARV
adherence, to estimate the association between additional pre-therapy counseling visits and our outcomes.
Results: 300 participants had records of counseling, of whom 231 (77%) completed visits prior to initiation of ARVs and 69
(23%) on or shortly after initiation. Median age was 33, 71% were female, and median CD4 was 133 cell/ml. Median 90-day
adherence was 95%. Participants who completed pre-therapy counseling visits had longer delays from ARV eligibility to
initiation (median 49 vs 14 days, p,0.01). In multivariable analyses, completing adherence counseling prior to ARV initiation
was not associated with average adherence .90% (AOR 0.8, 95%CI 0.4–1.5), absence of treatment gaps (AOR 0.7, 95%CI
0.2–1.9), or HIV viremia (AOR 1.1, 95%CI 0.4–3.1).
Conclusions: Completion of adherence counseling visits prior to ARV therapy was not associated with higher adherence in
this cohort of HIV-infected patients in Uganda. Because mortality and loss-to-follow-up remain high in the pre-ARV period,
policy makers should reconsider whether counseling can be delivered with ARV initiation, especially in patients with
advanced disease.
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Introduction
From 2005 through 2009, the number of people in low income
countries taking HIV antiretroviral medications (ARVs) increased
over 5-fold to 5.2 million [1]. Despite this, early outcomes for
HIV-infected patients remain sub-optimal, primarily in the peri-
ARV initiation period [2,3,4]. A particular weakness of HIV
programs is the failure to link patients to care after establishing
ARV eligibility, when approximately 1 in 3 patients are lost to
follow up in sub-Saharan Africa [5,6,7,8]. Causes of such failures
are complex. Structural barriers such as cost and availability of
transportation are commonly cited [9,10,11,12].
Adherence counseling is an important component of HIV care
[13]. Repeated adherence counseling visits in patients with
advanced disease prior to starting therapy, however, delays ARV
initiation and may contribute to the high rate of attrition prior to
initiation of ARVs. Recommendations calling for delay of ARV
initiation until after completion of adherence counseling are
commonly found in national HIV guidelines in sub-Saharan
Africa [14,15,16,17,18,19]. We performed an analysis of the effect
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39894of pre-therapy adherence counseling versus counseling on or after
initiation of ARVs on adherence and viral suppression during the
first three months of therapy in a cohort of patients initiating
ARVs in rural Uganda.
Methods
Ethics Statement
All participants provided written informed consent to partici-
pate in the study, which was reviewed by the institutional ethics
review committees of Mbarara University of Science and
Technology, the Ugandan National Council for Science and
Technology, Massachusetts General Hospital, and the University
of California, San Francisco.
Study Procedures
Study participants were members of the Uganda AIDS Rural
Treatment Outcomes study (UARTO), a prospective cohort
designed to measure predictors of ARV adherence in rural
Uganda. HIV-infected patients older than 17 years who are
initiating ARVs at the Immune Suppression Syndrome Clinic
(ISS) of Mbarara Regional Referral Hospital were eligible for
enrollment. An electronic medical record documented all clinic
encounters.
Participants were enrolled on the day of ARV initiation. Blood
draws for CD4 count and viral load were performed at baseline
and every 3 months. Medication adherence was measured with
Medication Event Monitoring System (MEMS) electronic pill
bottle monitors (Aardex Group, Sion, Switzerland).
Study Measures
Pre-adherence counseling was defined as any counseling session
entitled or including ‘‘ARV Counseling’’ which occurred prior to
the date of ARV initiation. Trained counselors perform all ARV
counseling visits, which are characterized by 20-minute sessions
covering dosing schedule, drug toxicities, importance of adherence
including prevention of resistance, and management of missed
doses. Patients who received their first episode of ARV counseling
on the day of ARV initiation were not considered to have had pre-
adherence counseling, as they did not require extra patient visits.
Counseling was measured by review of the electronic medical
record for ARV counseling visits after 2007, when counseling
forms were introduced in the clinical practice. For patients with no
record of ARV-adherence counseling in the electronic medical
record, we performed chart review to minimize the probability of
misallocation bias.
We measured time delay to ARV initiation as the time from
ARV eligibility to first receipt of ARVs. Eligibility for ARVs was
defined as the date of first CD4 count result below 250, the
threshold for initiation in Uganda during the study period. For
patients who did not have a CD4 result prior to initiation, we
defined time of ARV eligibility as the date of their first counseling
session.
We measured adherence over 3 months because most patients
in both groups received counseling around the time of initiation,
and studies have found that the effect of adherence education
declines with time [20]. For our outcomes of interest, we defined
poor adherence using two measurements: average adherence in
the first three months of therapy ,90% and absence of treatment
gaps .72 hours in the first three months of therapy. For a third
outcome, we defined virologic suppression as a viral load ,400
copies/ml at the three-month blood draw visit.
Statistical Analyses
Demographic and clinical characteristics were summarized by
presence or absence of pre-treatment adherence counseling.
Comparisons of summary characteristics across the two groups
were made with chi-square testing for categorical variables and
non-parametric Mann-Whitney tests for continuous variables. For
binary outcomes, we performed logistic regression to detect an
association between the outcome and presence or absence of pre-
adherence counseling. All analyses were done using univariable
modeling and again with multivariable modeling adjusted for
known predictors of adherence including age, sex, travel time,
employment status, socioeconomic status as measured by an asset
ownership index [21], year of ARV initiation, baseline CD4 count,
and history of opportunistic infection. To assess the robustness of
our findings to further covariate adjustment, we did additional
modeling to include depression, as measured by a score of ,1.75
on the Hopkins Symptoms Score Checklist [22], and alcohol use
with the AUDIT-C screen [23] in the multivariable model. These
variables were not in the primary model because even though they
may be related to adherence [24], they are likely affected by pre-
ART counseling, so we would potentially be conditioning on part
of the effect of interest. We also performed chi-squared testing to
measure an association between our measures of adherence and
virologic suppression to confirm a relationship between the two.
Data analyses were performed using Stata Version 11.2 (Stata-
Corp, College Station, TX).
Results
A total of 300 of 521 total participants in the UARTO study
enrolled after 2007 and had records of adherence counseling in the
chart or electronic database. Two hundred thirty-one participants
(77%) received adherence counseling prior to the initiation of
ARVs. Of the remaining 69 patients, 88% received adherence
counseling on the day of initiation. The median age of the cohort
was 33 years (IQR 28–40), 71% were female, and median baseline
CD4 count was 133 cell/microL (IQR 93–203). Median 90-day
adherence in the cohort was 95% (IQR 85–98%), and 66% had
adherence greater than 90%. There were no significant differences
between those who received pre-treatment counseling and those
who did not in terms of gender, age, baseline CD4, socioeconomic
status, time travel to clinic, employment, history of opportunistic
infection, or depression (Table 1). Participants who did not receive
counseling were more likely to enroll after 2008 (71% vs 45%,
p,0.01), and more likely to have a positive AUDIT-C alcohol
screen (30 vs 16%, p=0.01).
Participants who completed adherence counseling visits prior to
therapy had significantly longer delays from ARV eligibility to
initiation (median 49 vs 14 days, p,0.01). This was also true in the
subset of patients with baseline CD4 counts ,100 cells (median 41
vs. 21 days, p=0.04).
In univariable analyses, completing pre-therapy adherence
counseling was not associated with average adherence .90%
(OR 0.7, 95%CI 0.4–1.3), absence of treatment gaps .72 hours
(OR 0.6, 95% CI 0.2–1.6), or HIV viremia (OR 1.0, 95%CI 0.4–
2.7). The lack of association for these outcomes persisted in
multivariable models adjusted for other predictors of adherence
(Table 2). Addition of alcohol use and depression as cofactors did
not affect the associations. In the entire cohort, participants with
treatment gaps .72 hours were more likely to have HIV viral load
.400 copies/ml at 3 months (23% vs 8%, p =0.01). There was a
non-significant increase in viremia for those with average
adherence less than 90% (13 vs 7%, p=0.12).
Pre-Treatment Counseling and ARV Adherence
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Patients initiating ARVs in this cohort in rural Uganda achieved
high levels of adherence and viral suppression regardless of
whether they received additional adherence counseling visits prior
to ARV initiation or adherence counseling at the time of ARV
initiation. Compared to adherence counseling delivered concur-
rent with ARV initiation, adherence counseling prior to ARV
initiation was associated with significant delays in initiation
therapy. Because this was a prospective study that enrolled
participants at the time of ARV initiation, lost to follow-up could
not be measured in the pre-treatment period. Multiple other
studies have documented high rates of mortality and losses to
follow up among eligible patients who have not initiated ARVs. At
the ISS Clinic in Mbarara, approximately 30% of ARV-eligible
patients during the period 2007-2009 failed to initiate ARVs
within one year [25]. Multiple additional studies in South Africa,
Malawi, Kenya, Ethiopia, and Mozambique have shown similarly
high rates of patient attrition and early mortality in the pre-
treatment period [8,26,27,28]. A recent systematic review of
retention rates for ARV eligible patients from 14 studies across
sub-Saharan Africa corroborated these findings with an estimated
median rate of attrition among ARV eligible patients of 32%
(range 14–84%) [29]. Despite presentation to HIV care centers,
diagnosis of HIV, and meeting clinical or laboratory criteria for
Table 1. Baseline demographic, socioeconomic and clinical characteristics in study cohort of patients initiating ARVs in rural
Uganda.
Characteristic
Completed Pre-Therapy
Adeherence Counseling
(n=231)
No Pre-Therapy Adherence
Counseling
(n=69) p-value
Any Adherence Counseling (%) 100 88.4 ,0.01
Percent Female (%) 73.2 62.3 0.08
Age (median, IQR) 33 (27–39) 33 (30–40) 0.29
Baseline CD4 (%) 0.26
,100 31.2 23.2
100–249 54.1 65.2
$250 14.6 11.6
Period of ARV Initiation (%) ,0.01
Prior to 2008 44.6 71.0
During or after 2008 55.4 29.0
Asset Index Quartile 0.81
1 26.6 26.1
2 27.1 23.2
3 24.9 30.4
4 21.4 20.3
Hours in Travel to Clinic (%) 0.80
,1 hour 58.4 55.1
1–2 hours 31.2 31.2
.2 hours 10.4 13.0
Unemployed at baseline (%) 32.0 20.6 0.07
Every History of Opportunistic
Infection (%)
41.7 45.6 0.57
AUDIT-C Alcohol Use Screen Positive 15.6 29.9 0.01
Hopkins Symptoms Checklist
Depression Score .1.75 (%)
28.7 33.8 0.41
Days from ARV Eligibility to
Initiation (median, IQR)
49 (27–83) 14 (0–75) ,0.01
Days from ARV Eligibility to Initiation
if CD4,100 (median, IQR)
41 (27–69); n=72 21 (0–50); n=16 0.04
Average ARV Adherence first
3 months of Therapy
94.8 95.6 0.81
Average ARV Adherence .90%
in first 3 months of Therapy (%)
64.3 72.1 0.26
Any ARV Treatment Gaps .72 hours
in first 3 months of Therapy (%)
11.7 7.3 0.29
Viral Load .400 copies/ml at
3 month Follow-up Visit (%)
9.7 9.5 0.97
doi:10.1371/journal.pone.0039894.t001
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ARVs and dying at the most critical stage of HIV disease.
When asked, patients often cite transportation costs as a primary
reason for difficulty engaging in care [9,10,11,29,30,31,32]. They
aresometimesforcedtochoosebetweenpurchasingbasicnecessities
and paying for transportation visits to clinic [10]. Given the costs to
patients associated witheach visit, efforts to minimize the number of
required visits might improve retention in care. Consistent with this
hypothesis, a randomized controlled trial in Uganda found a
decrease in completion of HIV testing from 99 to 68% in
hospitalized patients randomized to immediate versus delayed
services at a return visit [33].
Most national HIV guidelines in sub-Saharan Africa recom-
mend some form of adherence counseling prior to initiation of
ARVs in eligible patients. Of the 11 countries in the region with
adult HIV infection prevalence .5% and publically available
treatment guidelines, six (Botswana, Lesotho, Mozambique,
Namibia, Tanzania, and Uganda) state that ARVs should be
withheld from patients who have not completed counseling visits
[14,15,16,17,18,19]. The benefit of adherence counseling must be
balanced by the risk of patient attrition during the pre-therapy
period, where the risks are highest in individuals with advanced
disease.
Multiple studies have shown benefit from adherence counseling
[20,34,35]. The most relevant study was a randomized controlled
trial of mandatory pre-therapy counseling in Kenya reported by
Chung et al. [36]. In contrast to our findings, the study
documented improved rates of medication adherence and
virologic suppression among patients receiving intensive versus
no medication adherence counseling. A key difference between the
prior study and ours was their use of no adherence counseling in
the control group, whereas 88% of patients in our delayed
counseling group received counseling on the day of ART
initiation. Presuming counseling has benefit, this suggests that
delivering counseling on the day of ARV initiation may be as
beneficial as several visits before ARV initiation. Notably, Chung
et al. reported a rate of loss to follow up or death of 12.5% prior to
initiation in those receiving counseling during mandatory pre-
treatment visits, compared to 4% in the control group.
While our study leverages objective adherence monitoring in a
prototypical sub-Saharan African clinic serving a rural popula-
tion, our sample is small, was derived from a single clinic, and
was only powered to detect a large effect size of pre-therapy
counseling on early treatment adherence. Though it is very
unlikely that pre-treatment counseling has a large effect on early
treatment adherence, further study of this intervention will be
important to evaluate for potentially important modest effects.
The absence of randomized adherence counseling may introduce
uncontrolled confounders despite inclusion of known predictors
of adherence in our multivariate regression model. A randomized
control trial comparing ARV adherence counseling prior to
versus concurrent with initiation of therapy would corroborate
these findings.
The high level of adherence seen in this study is characteristic of
many sub-Sahara African treatment settings [24,37]. High
adherence creates a ceiling effect with respect to the ability to
detect an additional benefit of pre-ART counseling. However,
these high levels of adherence also question the marginal benefit of
pre-ART adherence counseling, especially when pre-ART coun-
seling delays therapy in patients with advanced disease. The
patients we studied received intensive adherence monitoring,
which may have altered adherence via a Hawthorne effect. While
the population we studied had sufficiently high adherence not to
benefit from pre-treatment adherence counseling, adherence
counseling may have important benefits in select populations with
lower adherence [13].
Our findings suggest that counseling at the time of ARV
initiation is associated with excellent adherence and that additional
adherence counseling visits prior to therapy might have at most a
modest additional effect on early adherence. Counseling for both
adherence and other health-related issues is a crucial aspect of
HIV care and should be promoted throughout the care of the
patient. However adherence counseling should not delay ARV
initiation in patients with advanced disease, given high rates of
death and attrition in the ARV eligibility period.
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